

Table 1: General baseline characteristics of the 179 patients

Characteristics	Total (%)	Cytotoxic group (N/%)	Cytotoxic + targeted group (N/%)	P-value
Arms of treatment	179	48 (26.8%)	131 (73.2%)	-
Age at diagnosis, years	26-89y	27-83y	26-89y	
Range				
Mean ¹	60.5y ± 13.2	63y ± 14.1	59.5y ± 12.9	0.130
Sex				
Males/females	103 (57.5%)/76 (42.5%)	28 (58%)/20 (42%)	75 (57%)/56 (43%)	0.947
Location of primary tumour				
Colorectal	152 (84.9%)	38 (79%)	114 (87%)	
Rectal	60.5y ± 13.2	63y ± 14.1	59.5y ± 12.9	0.470
Location of metastases				
Liver only	50 (28%)	21 (44%)	29 (22%)	
Liver and others	76 (43%)	8 (17%)	68 (52%)	0.002
Non liver	53 (29%)	19 (39%)	34 (26%)	
Number of metastatic sites				
1	92 (52%)	40 (85%)	52 (40%)	
≥2	86 (48%)	7 (15%)	79 (60%)	0.044
KRAS gene status				
Wild	93 (52%)	11 (23%)	82 (63%)	
Mutated	27 (15.1%)	2 (4%)	25 (19%)	0.001
ND*	59 (33%)	35 (73%)	24 (18%)	
Tumour markers				
CEA only	55 (31%)	10 (21%)	45 (34%)	
CA19.9 only	11 (6%)	3 (6%)	8 (6%)	
Both increased	50 (28%)	7 (15%)	43 (33%)	0.001
Neither increased	63 (35%)	28 (58%)	35 (27%)	
Duration of treatment or follow up (in months) (All lines combined)	Median: 30.9 months Mean: 34.7 months ± 19.2 Min: 3.0 months Max: 71.5 months	Median: 36.5 months Mean: 36.1 months ± 21.2 Min: 3.0 months Max: 71.5 months	Median: 30.4 months Mean: 34.2 months ± 18.5 Min: 3.5 months Max: 69.0 months	0.473

*Lack of appropriate consent or lack of samples, ¹Data are in % or median (± standard deviation), CEA: CarcinoEmbryonic Antigen, CA19.9: Cancer antigen.